Jeffrey William Henderson Sells 5,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $50.01, for a total value of $500,100.00.

Halozyme Therapeutics Stock Up 0.9 %

Shares of HALO traded up $0.49 during trading hours on Tuesday, hitting $56.77. The stock had a trading volume of 716,947 shares, compared to its average volume of 1,357,498. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The firm has a market capitalization of $7.22 billion, a P/E ratio of 18.80, a price-to-earnings-growth ratio of 0.43 and a beta of 1.25. The firm has a 50 day simple moving average of $51.00 and a 200-day simple moving average of $54.35. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in shares of Halozyme Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock worth $175,194,000 after purchasing an additional 30,901 shares in the last quarter. Congress Asset Management Co. raised its holdings in Halozyme Therapeutics by 446.5% during the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after buying an additional 1,988,238 shares during the last quarter. Boston Trust Walden Corp lifted its stake in shares of Halozyme Therapeutics by 28.0% in the fourth quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock valued at $41,790,000 after buying an additional 191,465 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Halozyme Therapeutics by 6.2% during the third quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company’s stock worth $31,204,000 after acquiring an additional 31,871 shares in the last quarter. Finally, Glenmede Trust Co. NA raised its holdings in shares of Halozyme Therapeutics by 28.9% in the 3rd quarter. Glenmede Trust Co. NA now owns 487,131 shares of the biopharmaceutical company’s stock worth $27,883,000 after acquiring an additional 109,283 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Piper Sandler raised their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. JMP Securities raised their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday. Wells Fargo & Company lowered their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.